Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: Processing, stability and prognostic value

Journal of Urology

Volumn 155, Issue 2, 1996, Pages 477-482

  De Reijke, Theo M ^a   De Boer, Elizabeth C ^a   Kurth, Karl Heinz ^a   Schamhart, Denis H J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

BCG vaccine; bladder neoplasms; cytokines; interleukins; tumor necrosis factor

Indexed keywords

BCG VACCINE; INTERLEUKIN 1BETA; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLADDER CARCINOMA; CANCER CYTODIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REGIONAL PERFUSION; TREATMENT OUTCOME;

EID: 0030051368     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66424-3     Document Type: Article

References (30)

1. Lamm, D. L., Griffith, G., Pettit, L. L. and Nseyo, U. O.: Current perspectives on diagnosis and treatment of superficial bladder cancer. Urology, 39: 301, 1992.
2. Böhle, A., Gerdes, J., Ulmer, A. J., Hofstetter, A. G. and Flad, H.-D.: Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J. Urol., 144: 53, 1990.
3. Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. and Smyth, J. F.: Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J. Urol., 147: 1636, 1992.
4. Böhle, A., Nowc, C., Ulmer, A. J., Musehold, J., Gerdes, J., Hofstetter, A. G. and Flad, H. D.: Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma. Cytokine, 2: 175, 1990.
5. De Boer, E. C., De Jong, W. H., Steerenberg, P. A., Aarden, L. A., Tetteroo, E., De Groot, E. R., Van Der Meijden, A. P., Vegt, P. D., Debruyne, F. M. and Ruitenberg, E. J.: Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol. Immunother., 34: 306, 1992.
6. De Boer, E. C., De Jong, W. H., Van Der Meijden, A. P., Steerenberg, P. A., Witjes, J. A., Vegt, P. D., Debruyne, F. M. and Ruitenberg, E. J.: Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol. Immunother., 33: 411, 1991.
7. Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. and Smyth, J. F.: Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J. Urol., 144: 1248, 1990.
8. Ratliff, T. L., Haaff, E. O. and Catalona, W. J.: Interleukin-2 production during intravesical bacille Calmette-Guérin therapy for bladder cancer. Clin. Immunol. Immunopath., 40: 375, 1986.
9. Schamhart, D. H., Kurth, K. H., de Reijke, T. M. and Vleeming, R.: BCG treatment and the importance of an inflammatory response. Urol. Res., 20: 199, 1992.
10. Böhle, A., Thanhäuser, A., Ulmer, A. J., Ernst, M., Flad, H.-D. and Jocham, D.: Dissecting the immunobiological effects of bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J. Urol., 150: 1932, 1993.
11. Ratliff, T. L.: Mechanisms of action of intravesical BCG for bladder cancer. Prog. Clin. Biol. Res., 310: 107, 1989.
12. Brosman, S. A.: The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ. J. Urol., 134: 36, 1985.
13. Morales, A., Eidinger, D. and Bruce, A. W.: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol., 116: 180, 1976.
14. Pagano, F., Bassi, P., Milani, C., Meneghini, A., Maruzzi, D. and Garbeglio, A.: A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J. Urol., 146: 32, 1991.
15. Morales, A., Nickel, J. C. and Wilson, J. W. L.: Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J. Urol., 147: 1256, 1992.
16. Badalament, R. A., Herr, H. W., Wong, G. Y., Gnecco, C., Pinsky, C. M., Whitmore, W. F., Jr., Fair, W. R. and Oettgen, H. F.: A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J. Clin. Oncol., 5: 441, 1987.
17. Brosman, S. A.: Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J. Urol., 128: 27, 1982.
18. Herr, H. W., Pinsky, C. M., Whitmore, W. F., Jr., Sogani, P. G., Oettgen, H. F. and Melamed, M. R.: Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumors. Urology, 25: 119, 1985.
19. Kelley, D. R., Haaff, E. O., Becich, M., Lage, J., Bauer, W. C., Bresner, S. M., Catalona, W. J. and Ratliff, T. L.: Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin. J. Urol., 135: 268, 1986.
20. Lamm, D. L., Thor, D. E., Stogdill, V. D. and Radwin, H. M.: Bladder cancer immunotherapy. J. Urol., 128: 931, 1982.
21. Pinsky, C. M., Camacho, F. J., Kerr, D., Geller, N. L., Klein, F. A., Herr, H. W., Whitmore, W. F., Jr. and Oettgen, H. F.: Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Cancer Treat. Rep., 69: 47, 1985.
22. Schellhammer, P. F., Ladaga, L. E. and Fillion, M. B.: Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder. J. Urol., 135: 261, 1986.
23. Torrence, R. J., Kavoussi, L. R., Catalona, W. J. and Ratliff, T. L.: Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer. J. Urol., 139: 941, 1988.
24. Kurth, K. H., Denis, L., Ten Kate, F. J. W., Sylvester, R., De Pauw, M., Bouffioux, C., Debruyne, F. M. J., Pavone-Macaluso, M. and Oosterlinck, W.: Prognostic factors in superficial bladder tumors. Probl. Urol., 6: 471, 1992.
25. de Boer, E. C., De Reijke, T. M., Schamhart, D. H., Vos, P. C. and Kurth, K. H.: Increased urinary albumin indicating urothelial leakage following intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. Urol. Res., 21: 423, 1993.
26. Lage, J. M., Bauer, W. C., Kelley, D. R., Ratliff, T. L. and Catalona, W. J.: Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guérin treatment of superficial bladder cancer. J. Urol., 135: 916, 1986.
27. Haaff, E. O., Catalona, W. J. and Ratliff, T. L.: Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J. Urol., 136: 970, 1986.
28. Fleischmann, J. D., Toossi, Z., Ellner, J. J., Wentworth, D. B., Ratliff, T. L. and Imbembo, A. L.: Urinary interleukins in patients receiving intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. Cancer, 64: 1447, 1989.
29. Catalona, W. J., Hudson, M. A., Gillen, D. P., Andriole, G. L. and Ratliff, T. L.: Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J. Urol., 137: 220, 1987.
30. Lamm, D. L., Crawford, E. D., Blumenstein, B., Crissman, J. D., Montie, J., Gottesman, J., Lowe, B., Sarosdy, M. F., Bohl, R. D., Weems, W. L., Grossman, H. B., Smith, J. A., Beck, T. M., Leimert, J. and Coltman, C. A.: Maintenance BCG immunotherapy of superficial bladder cancer: a randomized prospective Southwest Oncology Group study. J. Urol., part 2, 147: 274A, abstract 242, 1992.